Updated Abeona Therapeutics (NASDAQ: ABEO) investor presentation furnished in 8-K filing

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Abeona Therapeutics Inc. filed a current report to share that it has prepared an updated investor presentation. The company plans to use this presentation in meetings with investors, analysts, and other interested parties.

The investor presentation, dated June 10, 2026, is furnished as Exhibit 99.1 under Regulation FD. Abeona notes that this material is being furnished rather than filed, meaning it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities filings unless specifically referenced.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Terms

Regulation FD, Investor Presentation, Section 18 of the Securities Exchange Act of 1934, Exhibit 99.1, +1 more

5 terms

Regulation FD regulatory

"Abeona Therapeutics Inc. is furnishing in this on an updated investor presentation (the “Investor Presentation”) that it expects to use…"

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

Investor Presentation financial

"A copy of the Investor Presentation is furnished herewith as Exhibit 99.1 and is incorporated into this Item 7.01 by reference."

An investor presentation is a carefully prepared talk or visual display that explains a company's business, goals, and financial performance. It helps investors understand how the company operates and its future prospects, much like a report card or progress update. These presentations are important because they provide transparency and help investors decide whether to support or invest in the company.

Section 18 of the Securities Exchange Act of 1934 regulatory

"shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended…"

Exhibit 99.1 regulatory

"A copy of the Investor Presentation is furnished herewith as Exhibit 99.1 and is incorporated into this Item 7.01 by reference."

Exhibit 99.1 is a label used in regulatory filings to identify a specific attached document, most often a company press release or investor presentation filed with securities regulators. For investors it matters because it marks an official, contemporaneous source of information directly tied to a filing—like the original news article pinned to a legal record—so traders and analysts treat it as an authoritative statement that can move a stock or clarify a company’s situation.

Inline XBRL technical

"104 | | Cover Page Interactive Data File (embedded within the Inline XBRL document)"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

06/10/2026 - 04:15 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 10, 2026

ABEONA THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Delaware

001-15771

83-0221517

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

6555 Carnegie Ave, 4th Floor

Cleveland, OH 44103

(Address of principal executive offices) (Zip Code)

(646) 813-4701

(Registrant’s telephone number, including area code)

N /A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of Each Class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.01 par value		ABEO		The Nasdaq Capital Market

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

Abeona Therapeutics Inc. is furnishing in this Current Report on Form 8-K an updated investor presentation (the “Investor Presentation”) that it expects to use, either in whole or in part, in connection with presentations to investors, analysts, and others. A copy of the Investor Presentation is furnished herewith as Exhibit 99.1 and is incorporated into this Item 7.01 by reference.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description

99.1		Abeona Therapeutics Inc. Presentation, dated June 10, 2026, entitled “Investor Presentation”
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Abeona Therapeutics Inc.
	(Registrant)

	By:	/s/ Joseph Vazzano
	Name:	Joseph Vazzano
	Title:	Chief Financial Officer

Date: June 10, 2026

Exhibit 99.1

Source: View Original Filing on SEC EDGAR

FAQ

What did Abeona Therapeutics (ABEO) disclose in its latest 8-K filing?

Abeona Therapeutics disclosed that it prepared an updated investor presentation for use with investors, analysts, and others. The presentation is furnished as Exhibit 99.1 and provides an overview of the company’s information as of June 10, 2026, under Regulation FD.

What is included in Abeona Therapeutics’ June 10, 2026 investor presentation?

The filing states that Abeona’s updated investor presentation, titled “Investor Presentation,” is attached as Exhibit 99.1. It is intended for use in meetings with investors, analysts, and other stakeholders, offering a structured summary of the company’s current information and messaging.

Is Abeona Therapeutics’ investor presentation considered filed with the SEC?

No, the investor presentation is expressly described as furnished, not filed, under Item 7.01 of the 8-K. As a result, it is not subject to Section 18 liability and is not automatically incorporated into other securities filings unless specifically referenced there.

Where can investors find Abeona Therapeutics’ updated investor presentation?

Investors can find the updated investor presentation as Exhibit 99.1 to the June 10, 2026 Form 8-K. It is part of the company’s public SEC filings and is incorporated into Item 7.01 of this report by reference for informational purposes.

Who signed Abeona Therapeutics’ June 10, 2026 Form 8-K?

The Form 8-K was signed on behalf of Abeona Therapeutics Inc. by Joseph Vazzano, its Chief Financial Officer. His electronic signature confirms the company’s authorization of the current report relating to the updated investor presentation furnished as Exhibit 99.1.

Filing Exhibits & Attachments

26 documents